Clinical Trial Update: M8891 First in Human in Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 first-in-human trial of M8891 in solid tumors has been terminated; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma
• Solid Tumors

Drugs mentioned

• M8891

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Advanced Solid Tumors, Metastatic Renal Cell Carcinoma | Phase 1 | Status: TERMINATED | Results posted: 2022-03-11